Organovo Holdings, Inc. (ONVO)

[WHP03]

$2.48, the low post surprise downround secondary (when guidance was still as high as $6.2MM, and as low as $4.5MM....) is very possibly the next test.

Problems: Q4 revs will almost certainly be lower than Q3, which was lower than Q2... could be 1/2 as much as Q3. Collaboration revs are done until new contracts are signed. Founding CEO leaves at the cusp of greatness (supposedly) to pursue 'other start-up opportunities'... makes no sense. New CEO paid less than outgoing, ineffective CEO... new CEO's background unclear as to how he is 'the one' to supercharge QoQ rev growth... 2018 guidance yet to be delivered. Will Q118 revs prove that $s left on the table in Q4 (per the company's comments) truly land on the Q1 income statement? Will Q2 show rev growth over Q1 (which should be spiked with Q4 $s) or will Q2 be flat vs. the hopefully inflated Q1 results? That won't be known until Nov. Will the company wisely find a partner for the liver patch? Or will they take the 100MM share OS share count and bloat it even further to 130-150MM in order to 'go it alone' over the next 3+ yrs?

All I care about at this point is seeing proven revenue growth, from tissue services, the true near-term core business (in the next 2-3 yrs). The rest is hope, speculation, chatter.